Abstract
Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient’s experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.
Highlights
The preceding article in this supplement provided clear support for the view that policy decisions by third-party payors restrict delivery of appropriate immunoglobulin GR
(IgG) treatment for patients with primary immunodeficiency disease (PI) and that effective action to reverse these policies requires coordinated actions by patients, physicians, and advocacy groups. Initiatives at both the local and national levels are important for ensuring that patients with PI retain or, in some cases, regain access to appropriate care with IgG
Diagnoses - There are a large number of PI diagnoses for which IGIV is indicated and recommended
Summary
Legislation proposed in Minnesota (Minnesota Statutes, chapters 62Q; 151; Coverage Of Plasma Protein Therapies And Home Nursing Services) states that any health plan offered by a health plan company must carry all FDA-approved plasma protein therapies in the formulary, provide coverage for home nursing services, complete pre-authorization within 24 h or one business day, and provide the option of receiving covered services at more than one pharmacy This legislation states that the Board of Pharmacy shall promulgate rules that include standards established by the MACs of the patient groups and professional societies representing individuals with PI. National advocacy may include actions by the IDF and its MAC, the AAAAI Committee on PI, and public awareness campaigns sponsored by the IDF and/or the JMF
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
